SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+7.96%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.32B
AUM Growth
+$1.32B
(+9.9%)
Cap. Flow
+$196M
Cap. Flow
% of AUM
14.83%
Top 10 Holdings %
Top 10 Hldgs %
42.53%
Holding
111
New
24
Increased
21
Reduced
23
Closed
30
Top Buys
| 1 |
NovoCure
NVCR
|
$81.6M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$65.8M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$46.1M |
| 4 |
Integra LifeSciences
IART
|
$28.9M |
| 5 |
AstraZeneca
AZN
|
$26.8M |
Top Sells
| 1 |
Sanofi
SNY
|
$35.3M |
| 2 |
IDEAYA Biosciences
IDYA
|
$33.2M |
| 3 |
Revolution Medicines
RVMD
|
$22M |
| 4 |
10x Genomics
TXG
|
$21.5M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$15.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alnylam Pharmaceuticals
ALNY
$58.5B
| $18.1M | 1.14% |
76,800
+17,400
| +29% | +$4.09M |
|
27
Adaptive Biotechnologies
ADPT
$2.01B
| $17.9M | 1.12% |
2,983,142
+1,870,393
| +168% | +$11.2M |
|
|
EDAP
28
EDAP TMS
EDAP
$84.5M
| $16.2M | 1.02% |
7,309,254
| – | – |
|
29
Takeda Pharmaceutical
TAK
$47.3B
| $15.6M | 0.98% |
1,180,000
+680,000
| +136% | +$9M |
|
30
Pharvaris
PHVS
$1.39B
| $15.6M | 0.98% |
814,652
+216,483
| +36% | +$4.15M |
|
31
Surmodics
SRDX
$487M
| $15.6M | 0.98% |
394,060
-243,638
| -38% | -$9.65M |
|
|
SEPN
32
Septerna, Inc. Common Stock
SEPN
$539M
| $15.5M | 0.97% |
+675,409
| New | +$15.5M |
|
33
Merus
MRUS
$4.98B
| $13.1M | 0.83% |
312,321
-86,000
| -22% | -$3.62M |
|
34
Orthofix Medical
OFIX
$592M
| $12M | 0.75% |
686,374
+79,441
| +13% | +$1.39M |
|
35
ANI Pharmaceuticals
ANIP
$2.03B
| $11.3M | 0.71% |
205,294
-63,706
| -24% | -$3.52M |
|
36
Verastem
VSTM
$569M
| $11.3M | 0.71% |
2,184,026
-643,937
| -23% | -$3.33M |
|
37
Protagonist Therapeutics
PTGX
$3.67B
| $10.6M | 0.67% |
+275,000
| New | +$10.6M |
|
38
Delcath Systems
DCTH
$385M
| $9.64M | 0.61% |
+801,000
| New | +$9.64M |
|
39
CG Oncology
CGON
$2.04B
| $9.42M | 0.59% |
328,585
-12,000
| -4% | -$344K |
|
40
Arcellx
ACLX
$3.85B
| $9.28M | 0.58% |
121,031
+28,000
| +30% | +$2.15M |
|
41
Eli Lilly
LLY
$657B
| $9M | 0.57% |
11,658
-7,642
| -40% | -$5.9M |
|
|
42
Revolution Medicines
RVMD
$7.1B
| $8.8M | 0.55% |
201,084
-503,500
| -71% | -$22M |
|
|
THTX
43
Theratechnologies
THTX
$149M
| $8.69M | 0.55% |
4,801,376
| – | – |
|
44
Nuvalent
NUVL
$5.52B
| $8.17M | 0.51% |
104,357
+30,000
| +40% | +$2.35M |
|
45
Vaxcyte
PCVX
$4B
| $8.11M | 0.51% |
99,050
+72,000
| +266% | +$5.89M |
|
46
Evolus
EOLS
$494M
| $7.7M | 0.48% |
697,158
-340,522
| -33% | -$3.76M |
|
47
Immunic
IMUX
$80.9M
| $7.29M | 0.46% |
7,293,007
| – | – |
|
48
Scholar Rock
SRRK
$3.14B
| $7.24M | 0.46% |
+167,543
| New | +$7.24M |
|
49
Castle Biosciences
CSTL
$696M
| $6.74M | 0.42% |
252,917
-409,415
| -62% | -$10.9M |
|
50
Myomo
MYO
$39.7M
| $5.8M | 0.36% |
+900,000
| New | +$5.8M |
|